Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASN002 Open-Label Extension in Atopic Dermatitis
NCT03654755Phase 2Terminated
- Sponsor
- Asana BioSciences, LLC
- Start
- Sep 2018
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of gusacitinib in atopic dermatitis (AD) (3 arms), sponsored by Asana BioSciences, LLC. Primary endpoint: Eczema Area Severity Index at 3 months. Started Sep 2018; status: terminated.
02
Drugs
gusacitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03654755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03654755.